Growing the love for investing
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Genoptix is a rapidly growing blood and bone marrow diagnostics company. It is reasonably valued at 13.75 times trailing eranings and its stock price has suffered a pullback recently. At $26.55, GXDX is close to its 52 week low. This company's only real challenge is whether it can maintain high prices for its services. I expect continuing volatility with a strong upside bias. This will create opportunities to score CAPS points.
Genoptix is brilliant at marketing and gaining loyalty from physicians by providing color printers to print lab reports which are very appealing according to a nurse friend working at an oncology office, but I don't believe insurers will continue to pay the high rates Genoptix is charging unless they can prove clinical relevance compared to other specialty labs providing similar services at a fraction of the cost. Didn't they mention on a previous investor call that they send out some testing needs to other labs because they don't do it inhouse themselves? What exactly do they do that is different from other cancer labs besides pretty reports?